Light can serve as a tunable trigger for neurobioengineering technologies, enabling probing, control, and enhancement of brain function with unmatched spatiotemporal precision. Yet, these technologies often require genetic or structural alterations o...
BACKGROUND AND OBJECTIVES: Early and cost-effective identification of amyloid positivity is crucial for Alzheimer's disease (AD) diagnosis. While amyloid PET is the gold standard, plasma biomarkers such as phosphorylated tau 217 (pTau217) provide a p...
There is an urgent need for rapid, affordable diagnostics for Alzheimer's disease (AD), particularly those that can detect phosphorylated Tau 181 (p-tau181)─a key biomarker─directly in plasma. We present a scalable, label-free electrochemical biosens...
Alzheimer's disease (AD) diagnosis hinges on detecting amyloid beta (Aβ) plaques and neurofibrillary tau (τ) tangles, typically assessed using PET imaging. While accurate, these modalities are expensive and not widely accessible, limiting their utili...
Alzheimer's disease is a progressive neurodegenerative disorder marked by cognitive decline, memory loss, and behavioral changes. Early diagnosis, particularly identifying Early Mild Cognitive Impairment (EMCI), is vital for managing the disease and ...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that significantly affects cognitive function. One widely used diagnostic approach involves analyzing patients' verbal descriptions of pictures. While prior studies have primarily f...
BACKGROUND: Alzheimer's disease (AD) is the principal cause of dementia and requires the early diagnosis of people with mild cognitive impairment (MCI) who are at high risk of progressing. Early diagnosis is imperative for optimizing clinical managem...
BACKGROUND: Given the high prevalence and cost of Alzheimer disease (AD), it is crucial to develop equitable interventions to address lifestyle factors associated with AD incidence (eg, depression). While lifestyle interventions show promise for redu...
Alzheimer's disease (AD) presents a pressing global health challenge, demanding improved strategies for early detection and understanding its progression. In this study, we address this need by employing survival analysis techniques to predict transi...
Alzheimer's disease (AD) presents a critical global health challenge, with current therapies offering limited efficacy and safety in halting disease progression. Gamma sensory stimulation (GSS) has emerged as a promising non-invasive neuromodulation ...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.